



RESEARCH ARTICLE

REVISED Interferon-gamma polymorphisms and risk of iron deficiency and anaemia in Gambian children [version 2; peer review: 2 approved]

Kelvin M. Abuga ¹, Kirk A. Rockett ², John Muthii Muriuki ^{1,3}, Oliver Koch ⁴, Manfred Nairz⁵, Giorgio Sirugo ⁶, Philip Bejon ^{1,7}, Dominic P. Kwiatkowski^{2,8,9}, Andrew M. Prentice¹⁰, Sarah H. Atkinson ^{1,7,11}

¹Kenya Medical Research Institute (KEMRI) Centre for Geographic Medicine Coast, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

²Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

³Open University, KEMRI-Wellcome Trust Research Programme – Accredited Research Centre, Kilifi, Kenya

⁴Infection Medicine, The University of Edinburgh, Edinburgh, UK

⁵Department of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria

⁶Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

⁷Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

⁸Wellcome Sanger Institute, Hinxton, Cambridge, UK

⁹Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK

¹⁰Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, The Gambia

¹¹Department of Paediatrics, University of Oxford, Oxford, UK

v2 First published: 02 Mar 2020, 5:40
<https://doi.org/10.12688/wellcomeopenres.15750.1>

Latest published: 02 Jun 2020, 5:40
<https://doi.org/10.12688/wellcomeopenres.15750.2>

Abstract

Background: Anaemia is a major public health concern especially in African children living in malaria-endemic regions. Interferon-gamma (IFN- γ) is elevated during malaria infection and is thought to influence erythropoiesis and iron status. Genetic variants in the IFN- γ gene (*IFNG*) are associated with increased IFN- γ production. We investigated putative functional single nucleotide polymorphisms (SNPs) and haplotypes of *IFNG* in relation to nutritional iron status and anaemia in Gambian children over a malaria season.

Methods: We used previously available data from Gambian family trios to determine informative SNPs and then used the Agena Bioscience MassArray platform to type five SNPs from the *IFNG* gene in a cohort of 780 Gambian children aged 2-6 years. We also measured haemoglobin and biomarkers of iron status and inflammation at the start and end of a malaria season.

Results: We identified five *IFNG* haplotype-tagging SNPs (*IFNG*-1616 [rs2069705], *IFNG*+874 [rs2430561], *IFNG*+2200 [rs1861493], *IFNG*+3234 [rs2069718] and *IFNG*+5612 [rs2069728]). The *IFNG*+2200C [rs1861493] allele was associated with reduced haemoglobin concentrations (adjusted β -0.44 [95% CI -0.75, -0.12]; Bonferroni adjusted $P = 0.03$) and a trend towards iron deficiency compared to wild-type at the end of the malaria

Open Peer Review

Reviewer Status

	Invited Reviewers	
	1	2
version 2 (revision) 02 Jun 2020		
version 1 02 Mar 2020	 report	 report
<p>1 John Michael Ong'echa, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya</p> <p>2 Laura Silvestri, San Raffaele Scientific Institute, Milan, Italy</p> <p>Any reports and responses or comments on the article can be found at the end of the article.</p>		

season in multivariable models adjusted for potential confounders. A haplotype uniquely identified by *IFNG*+2200C was similarly associated with reduced haemoglobin levels and trends towards iron deficiency, anaemia and iron deficiency anaemia at the end of the malaria season in models adjusted for age, sex, village, inflammation and malaria parasitaemia.

Conclusion: We found limited statistical evidence linking *IFNG* polymorphisms with a risk of developing iron deficiency and anaemia in Gambian children. More definitive studies are needed to investigate the effects of genetically influenced IFN- γ levels on the risk of iron deficiency and anaemia in children living in malaria-endemic areas.

Keywords

Interferon-gamma, malaria, iron deficiency, anaemia, ferritin, hepcidin, zinc protoporphyrin, transferrin saturation, iron, *IFNG*, genetic polymorphisms, Africa, children



This article is included in the [KEMRI | Wellcome Trust gateway](#).

Corresponding authors: Kelvin M. Abuga (KMokaya@kemri-wellcome.org), Sarah H. Atkinson (satkinson@kemri-wellcome.org)

Author roles: **Abuga KM:** Data Curation, Formal Analysis, Methodology, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Rockett KA:** Data Curation, Investigation, Methodology, Resources, Software, Supervision, Writing – Review & Editing; **Muriuki JM:** Formal Analysis, Writing – Review & Editing; **Koch O:** Methodology, Writing – Review & Editing; **Nairz M:** Writing – Review & Editing; **Sirugo G:** Methodology, Resources, Writing – Review & Editing; **Bejon P:** Investigation, Methodology, Writing – Review & Editing; **Kwiatkowski DP:** Methodology, Resources, Software, Supervision, Writing – Review & Editing; **Prentice AM:** Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Review & Editing; **Atkinson SH:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by Wellcome [110255 to SHA; 212600 to KMA] and core awards to the KEMRI-Wellcome Trust Research Programme [203077], the Wellcome Centre for Human Genetics [203141] and the Wellcome Sanger Institute [206194]. KMA and JMM were supported by the DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from Wellcome [107769] and the UK government. The Gambian studies were supported by the National Institute of Child Health and Development, Bill and Melinda Gates Foundation, core funding MC-A760-5QX00 to the MRC Unit, The Gambia/MRC International Nutrition Group by the UK MRC and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Abuga KM *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Abuga KM, Rockett KA, Muriuki JM *et al.* **Interferon-gamma polymorphisms and risk of iron deficiency and anaemia in Gambian children [version 2; peer review: 2 approved]** Wellcome Open Research 2020, 5:40 <https://doi.org/10.12688/wellcomeopenres.15750.2>

First published: 02 Mar 2020, 5:40 <https://doi.org/10.12688/wellcomeopenres.15750.1>

REVISED Amendments from Version 1

To address the comments and suggestions made by the reviewers, we have:

1. Added the age range of participants in the methods section of the abstract.
2. Included the sample collection time in the Methods section under Study design.
3. Added data on hepcidin/ferritin and transferrin saturation/hepcidin ratios to [Table 1](#) and [Table 3](#).
4. Added a Supplementary file (Extended datafile 3) with iron and haemoglobin data of children with sickle cell trait and glucose-6-phosphate dehydrogenase deficiency.

Any further responses from the reviewers can be found at the end of the article

Introduction

Malaria and iron deficiency are major public health problems for children living in sub-Saharan Africa. The majority (94%) of the 405,000 global deaths due to malaria in 2018 occurred in sub-Saharan Africa, where up to 24% of the population have malaria parasitaemia at any given time^{1,2}. In this region, iron deficiency (ID) and anaemia are highly prevalent^{3,4}, and may lead to impaired brain development^{5,6}, while iron deficiency anaemia (IDA) is a leading cause of years lived with disability in African children⁷. Increasing evidence suggests that malaria may be contributing to ID and IDA^{8,9}. Previous studies reported that the prevalence of ID and IDA increased over the malaria season in Gambian and Kenyan children^{10,11}, and decreased with the interruption of malaria transmission in the Kenyan highlands¹².

Multiple factors may contribute towards the development of ID and IDA following a malaria infection. One such factor is interferon-gamma (IFN- γ), which is induced during acute and persistent malaria infection¹³. Among other type 1 responses, IFN- γ is involved in regulating erythropoiesis^{14–16} and iron-regulatory proteins^{17–20}. IFN- γ has also been reported to increase the expression of hepcidin¹⁷, and divalent metal transporter 1 (DMT1)¹⁹, while suppressing ferroportin^{18,19}, ferritin²⁰, and transferrin receptors^{19,20}. This regulation of iron proteins may be aimed at starving invading pathogens of iron, a critical nutrient for pathogen growth, but could also play an important role in the pathogenesis of ID and IDA. Indeed, higher IFN- γ levels have been reported in Kenyan children with severe malarial anaemia²¹.

Single nucleotide polymorphisms (SNPs) in the IFN- γ gene (*IFNG*) on chromosome 12q14 have been associated with increased production of IFN- γ ^{22,23}, and with susceptibility to severe malaria^{24,25}. Despite evidence that malaria induces the production of IFN- γ ¹³ and that this cytokine influences iron regulation^{17–20}, it is not known whether variation in the *IFNG* gene influences the risk of ID and IDA among children in malaria-endemic areas. We investigated SNPs and haplotypes in the *IFNG* gene locus in relation to nutritional iron status and anaemia in a cohort of 780 Gambian children prior to and at the

end of a malaria season, using an approach based on informative SNPs and Agena Bioscience MassArray platform typing.

Methods

Study area

The study was conducted in ten rural villages in the West Kiang region of The Gambia at the start (July 2001) and end (December 2001/January 2002) of a malaria season, as previously described²⁶. Malaria incidence is highly seasonal in The Gambia, with the majority of cases occurring between September and December. The study participants were from the Mandinka and Fulani ethnic groups. All of the Fulani children were located in a single village and ethnic group was accounted for in all analyses by adjusting for village.

Study design

We used previously collected data from a cohort of 780 children aged two to six years, recruited at the start of a malaria season as previously described²⁶. All children had a clinical examination and a blood sample collected in the morning between 6 and 11 am for full blood count, malaria film, and biomarkers of iron status and inflammation at the start and end of the malaria season. Children with pyrexia (temperature $\geq 37.5^{\circ}\text{C}$) had appropriate clinical investigations, clinical treatment and a blood sample taken 2 weeks later after recovery from illness. All children received a 3-day course of mebendazole for possible hookworm infection at recruitment.

Laboratory procedures

Haemoglobin (Medonic CA 530 Haemoglobinometer) and zinc protoporphyrin (ZnPP) levels (Aviv Biomedical Hematofluorometer) were measured within 24 hours of sample collection. Hepcidin (Hepcidin-25 [human] EIA kit; Bachem), ferritin (IMx ferritin assay, Microparticle Enzyme Immunoassay; Abbot Laboratories), soluble transferrin receptor (sTfR, Human sTfR ELISA; R&D Systems), serum iron, unsaturated iron binding capacity (UIBC, Ferrozine-based photometry and colorimetry; Hitachi 911 automated analyzer), and α_1 -antichymotrypsin (ACT, immunoturbidimetry, Cobas Mira Plus Bioanalyzer, Roche) were assayed according to the manufacturers' instructions from plasma samples stored at -80°C . Transferrin saturation (TSAT) was calculated from plasma iron and UIBC (TSAT = [plasma iron/ (UIBC + plasma iron)] X 100)²⁷. Hepcidin/ferritin and TSAT/hepcidin ratios were also calculated²⁸. Giemsa-stained thick and thin blood films were examined for *Plasmodium falciparum* and other *Plasmodium* species at the start and end of the malaria season.

SNPs and haplotype construction

Genotypes were determined on whole-genome amplified DNA (primer extension pre-amplification) by the Agena Bioscience MassArray platform (formerly SEQUENOM) using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry as previously described²⁵. Details of the primer sequences and assays are given in *Extended datafiles 1* and *2*²⁹. The most informative haplotype-tagging SNPs (htSNPs) to type in Gambian subjects were identified by analysing

the pattern of linkage disequilibrium (LD) in the *IFNG* gene loci using previously available data from 32 Gambian family trios^{25,30}. The PHASE program (<http://stephenslab.uchicago.edu/software.html>) version 2.1 was used to infer haplotypes from the genotypes of the study population and estimate the frequency of each inferred haplotype³¹. The entropy maximization method was used to identify htSNPs that described >90% of the observed haplotypic diversity in this gene region³⁰. The HaploXT program (<http://www.sph.umich.edu/csg/abecasis/GOLD/docs/haploxt.html>) was used to estimate pairwise LD statistics. Sickle cell (HbS, rs334) and glucose-6-phosphate deficiency (G6PD) deficiency (rs1050828 and rs1050829) were also genotyped using the Agena Bioscience MassArray platform.

Definition of terms

Inflammation was defined as ACT >0.6 g/L. ID was defined as ferritin <12 µg/L or <30 µg/L in the presence of inflammation or <15 µg/L in children ≥5 years³², anaemia as Hb<11.0 g/dL (or Hb <11.5 g/dL in children ≥5 years) and IDA as ID plus anaemia³³.

Statistical analyses

Statistical analyses were conducted using STATA 15.1 (Stata-Corp. College Station, Texas, USA). Categorical data were expressed as proportions with corresponding percentages. Pearson chi-squared test was used to compare the prevalence of malaria and iron status (ID, IDA and anaemia) at the start and end of the malaria season. Changes in haemoglobin levels and markers of iron status over the malaria season were assessed using the paired t-test. Biological data that were not normally distributed were log-transformed, and geometric means were calculated from original untransformed values.

Log-transformed markers of iron status and risk of ID, IDA and anaemia were analysed using univariable and multivariable linear and logistic regression models, as appropriate. Multivariable regression models were adjusted for age (grouped by year), sex, village (which also acted as a proxy for ethnic group), malaria parasitaemia and ACT at the start and end of the malaria season. The Bonferroni correction for multiple testing³⁴ was applied when the five SNPs and six haplotypes were considered individually as independent factors. For multivariable analyses, P values are noted as adj. P for non-Bonferroni corrected analyses and as Bonferroni adj. P for multivariable analyses that are Bonferroni corrected, and for univariable models P values are similarly presented as P or Bonferroni P if Bonferroni corrected. All analyses were considered statistically significant at P <0.05.

Ethics

Individual written informed consent was obtained from children's parents or guardians and the study was approved by The Gambian Government and the Medical Research Council Ethics Review Committee (874/830).

Results

Characteristics of participants

A total of 756 children, including 403 males (53%) and 353 females (47%), were followed up to the end of the malaria season. Most of the children were from the Mandinka ethnic group (n = 681; 90%, compared to Fulani n = 75; 10%). A total of 99/751 (13.2%) children carried sickle cell trait (HbAS) and 136/683 (19.9%) children G6PD deficiency and the effects of these polymorphisms on iron status and anaemia are shown in *Extended datafile 3*²⁹. At the start of the malaria season we found little difference in iron status in children with HbAS and G6PD deficiency compared to those with wild-type. At the end of the malaria season, children carrying HbAS had lower zinc protoporphyrin levels (97.0 [95% CI 87.0, 108.2]) compared to those with HbAA (115.9 [95% CI 110.6, 121.3]; adj. P = 0.05) and children with G6PD deficiency had lower haemoglobin levels (9.7 g/dl [95% CI 9.4, 10.0]) than those with G6PD wild-type genotype (10.0 g/dl [95% CI 9.9, 10.2]; adj. P = 0.01). The prevalence of ID and IDA increased over the malaria season (from 20.6% to 31.6% and from 11.9% to 21.7%, respectively), as previously reported^{11,26}. Individual markers of iron status also reflected an increase in ID over the malaria season. We found that hepcidin and hepcidin/ferritin ratio decreased while the TSAT/hepcidin ratio increased across the malaria season in keeping with the need for increased erythropoiesis and increased rates of iron absorption at the end of the malaria season. **Table 1** summarises the characteristics of the study population and their iron status at the beginning and end of the malaria season.

IFNG single nucleotide polymorphisms and associations

We identified five *IFNG* haplotype tagging SNPs at positions *IFNG*-1616 (rs2069705), *IFNG*+874 (rs2430561), *IFNG*+2200 (rs1861493), *IFNG*+3234 (rs2069718) and *IFNG*+5612 (rs2069728) relative to the ATG start codon (**Figure 1**, *Extended datafile 1*²⁹). All of the *IFNG* SNPs were in Hardy Weinberg equilibrium. The *IFNG*+2200C (rs1861493, n=97) allele was associated with a reduced risk of malaria parasitaemia at the end of the malaria season (adj. OR 0.40 [95% CI 0.21, 0.77]; Bonferroni adj. P=0.03) but not at the start. The other *IFNG* SNPs were not associated with malaria parasitaemia at either time point (*Extended datafile 4*²⁹). The *IFNG* SNPs were not associated with HbAS or G6PD genotypes following Bonferroni correction in adjusted models. The *IFNG*+874T and *IFNG*+3234C alleles were associated with the Fulani ethnic group (OR 2.22 [95% CI 1.49, 3.31] Bonferroni P = 0.0005 and OR 1.56 [95% CI 1.09, 2.24]; Bonferroni P = 0.045, respectively). The minor allele frequencies by ethnic group are presented in *Extended datafile 1*²⁹.


Associations with iron and anaemia

We found that the *IFNG* SNPs were not associated with ID, IDA or anaemia at the start of the malaria season in multivariable logistic regression analyses adjusted for age, sex, village, ACT and malaria parasitaemia following Bonferroni adjustment (*Extended datafile 5*²⁹).

Table 1. Participant characteristics and iron status at the start and end of the malaria season.

Characteristic	Start	End
Age months, median (IQR)	46.11 (34.83, 59.17)	51.37 (40.47, 64.20)
Sex, Female (%)	353/756 (46.7%)	322/700 (46.0%)
Malaria parasitaemia (%)	89/754 (11.8%)	179/698 (25.6%)
Iron status*		
Iron deficiency ^a	151/734 (20.6%)	216/684 (31.6%)
Iron deficiency anaemia ^b	86/720 (11.9%)	146/673 (21.7%)
Anaemia ^c	475/736 (64.5%)	504/691 (72.9%)
Iron biomarkers**		
Hepcidin (ng/ml)	11.1 (9.9, 12.4)	4.2 (3.7, 4.8)
Hepcidin/ferritin	0.44 (0.40, 0.48)	0.20 (0.18, 0.23)
TSAT/hepcidin (%/ng/ml)	0.20 (0.18, 0.23)	1.16 (1.03, 1.31)
Ferritin (µg/L)	25.2 (23.6, 26.8)	20.6 (19.1, 22.2)
ZnPP (µmol/mol Hb)	86.4 (82.9, 90.0)	113.4 (108.7, 118.3)
sTfR (mg/L)	3.45 (3.36, 3.54)	4.16 (4.05, 4.28)
UIBC (µmol/L)	56.8 (55.7, 57.8)	62.7 (61.3, 64.2)
Serum iron (µmol/L)	8.6 (8.3, 9.0)	8.4 (8.2, 8.7)
TSAT (%)	12.9 (12.4, 13.4)	11.6 (11.1, 12.1)
Hb (g/dL)	10.6 (10.5, 10.7)	10.0 (9.8, 10.1)

[†] Frequency and percentages are shown. ****** Geometric means and 95% CIs are shown. ^aIron deficiency was defined as ferritin <12µg/l (or ferritin <30µg/l in the presence of inflammation or <15 µg/L in children ≥ 5years)³²; ^b iron deficiency anaemia as iron deficiency^a and anaemia^c; ^c anaemia as haemoglobin <11.0 g/dL or haemoglobin <11.5 g/dL in children ≥ 5years. ZnPP, zinc protoporphyrin; TSAT, transferrin saturation; sTfR, soluble transferrin receptor; UIBC, unsaturated iron binding capacity; and Hb, haemoglobin.

**Figure 1. Schematic representation of the *IFNG* gene locus.** The *IFNG* single nucleotide polymorphisms (SNP) are designated according to the nucleotide position relative to the transcriptional starting site of *IFNG*.

The *IFNG* SNPs were similarly not significantly associated with ID, IDA or anaemia at the end of the malaria season after Bonferroni correction. The *IFNG*+2200C allele (rs1861493) was associated with trends towards increased risk of anaemia (adj. OR 1.86 [95% CI 1.02, 3.38]; adj. P = 0.04), IDA (adj. OR 1.81 [95% CI 1.01, 3.25]; adj. P = 0.05), and ID (adj.

OR 1.63 [95% CI 0.95, 2.80]; adj. P = 0.08) in multivariable logistic regression models, but not after Bonferroni correction (Table 2). Children carrying the *IFNG*+2200C allele had lower haemoglobin levels (9.7 g/dl [95% CI 9.4, 10.1]) compared to those with the *IFNG*+2200 TT genotype (10.0 g/dl [95% CI 9.8, 10.1]; adj. P = 0.006 and Bonferroni adj. P = 0.03),

Table 2. *IFNG* genotypes and risk of iron deficiency, iron deficiency anaemia and anaemia at the end of the malaria season.

dbSNP number	Genotype	No (%) ^a	Iron Deficiency ^b			Iron Deficiency Anaemia ^c			Anaemia ^d		
			OR (95% CI) [†]	Adj P [†]	Bf adj P [*]	OR (95% CI) [†]	Adj P [†]	Bf adj P [*]	OR (95% CI) [†]	Adj P [†]	Bf adj P [*]
rs2069705	IFNG -1616 CC	206 (29.9)	Reference			Reference			Reference		
	IFNG -1616 CT	332 (48.2)	0.82 (0.53, 1.28)	0.40	1	0.62 (0.38, 1.02)	0.06	0.31	0.96 (0.59, 1.53)	0.85	1
	IFNG -1616 TT	151 (21.9)	0.60 (0.34, 1.05)	0.07	0.37	0.53 (0.32, 1.09)	0.09	0.45	0.88 (0.50, 1.55)	0.66	1
rs2430561	IFNG+874 AA	509 (71.4)	Reference			Reference			Reference		
	IFNG+874 AT	182 (25.5)	0.71 (0.44, 1.14)	0.22	0.76	0.75 (0.45, 1.25)	0.27	1	0.93 (0.59, 1.48)	0.76	1
	IFNG+874 TT	22 (3.1)	0.29 (0.09, 0.99)	0.05	0.24	0.37 (0.09, 1.44)	0.15	0.75	0.62 (0.24, 1.63)	0.33	1
rs1861493 ^e	IFNG +2200 TT	598 (86.0)	Reference			Reference			Reference		
	IFNG +2200 CT/CC	97 (14.0)	1.63 (0.95, 2.80)	0.08	0.38	1.81 (1.01, 3.25)	0.05	0.23	1.86 (1.02, 3.38)	0.04	0.22
rs2069718	IFNG +3234 TT	393 (54.7)	Reference			Reference			Reference		
	IFNG +3234 CT	268 (37.3)	0.87 (0.58, 1.32)	0.52	1	0.89 (0.56, 1.41)	0.62	1	0.95 (0.62, 1.45)	0.82	1
	IFNG +3234 CC	58 (8.1)	0.79 (0.39, 1.60)	0.51	1	0.73 (0.33, 1.63)	0.44	1	0.67 (0.34, 1.32)	0.25	1
rs2069728	IFNG +5612 CC	326 (47.0)	Reference			Reference			Reference		
	IFNG +5612 CT	302 (43.6)	0.85 (0.57, 1.28)	0.44	1	0.76 (0.48, 1.19)	0.22	1	0.94 (0.62, 1.42)	0.76	1
	IFNG +5612 TT	65 (9.4)	0.97 (0.48, 1.96)	0.93	1	0.47 (0.20, 1.12)	0.09	0.45	0.94 (0.45, 1.95)	0.87	1

^a Values are number (%) in each group; ^b Ferritin <12µg/l (or ferritin<30µg/l in the presence of inflammation or <15 µg/L in children ≥5 years)³²; ^c Iron deficiency^b and anaemia^d; ^d Haemoglobin<11.0g/dL (or haemoglobin<11.5g/dL in children ≥5years); ^e The mutant alleles for IFNG+2200 were combined because of the low frequency of IFNG+2200CC (n=4) in the study population; [†] Odds ratios (OR) and P values were derived by multivariable logistic regression adjusted for age, sex, village (a proxy for location and ethnic group), α₁-antichymotrypsin level and the presence of malaria parasites on blood film; ^{*} P values additionally adjusted for Bonferroni correction for multiple testing.

as well as a trend towards ID in other markers of iron status at the end of the malaria season in adjusted linear regression models (Table 3).

IFNG haplotypes

Haplotype analysis identified ten haplotypes (four with less than 1% population frequency) resolved by SNPs at nucleotide positions -1616, +874, +2200, +3234 and +5612 in the *IFNG* gene locus (Figure 1). Six haplotypes accounted for most of the variation. The wild-type haplotype (haplotype 1, *IFNG*-CATTC) was present at a frequency of 35% in the Gambian children, while haplotype 6 (*IFNG*-CACTC), uniquely identified by the *IFNG*+2200 SNP, was present at a frequency of 7%. Using haplotype 1 as the reference, haplotype 6 was associated with a trend towards increased risk of ID (adj. OR 1.58 [95% CI 0.93, 2.69]), IDA (adj. OR 1.71 [95% CI 0.94, 3.10]) and anaemia (adj. OR 1.67 [95% CI 0.93, 3.01]) at the end of the malaria season (Table 4). Haplotype 6 was also associated with reduced haemoglobin concentrations (adj. β -0.48 [95% CI -0.79, -0.18]; P = 0.002) and TSAT (adj. β -0.15 [95% CI -0.27, -0.03]; P = 0.02), and higher ZnPP levels (adj. β 0.06 [95% CI 0.01, 0.12]; P = 0.02) and a trend towards

reduced ferritin levels compared to the wild-type haplotype (Table 5).

Discussion

In this study we observed an increase in the prevalence of ID, IDA and anaemia across the malaria season in Gambian children. Dietary iron insufficiency may be an important cause since the malaria season also coincides with the 'hungry season' in The Gambia when there is a scarcity of staple foods. We hypothesized that IFN-γ, a pro-inflammatory cytokine induced during malaria infection¹³, might play a role in influencing the risk of ID and anaemia in children exposed to malaria. In addition to directly reducing erythrocyte half-life¹⁵, evidence suggests that IFN-γ induces hepcidin and inhibits ferroportin, hence reducing iron absorption and promoting sequestration of iron in macrophages^{17,19}. Consequently, high levels of IFN-γ induced during malaria infections may concomitantly lead to ID and anaemia.

We found that the *IFNG*+2200C (rs1861493) allele, located at intron 3 of the *IFNG* gene, was associated with reduced haemoglobin levels and a trend towards ID, IDA and anaemia

Table 3. *IFNG*+2200 SNPs and markers of iron status at the end of the malaria season.

Iron Marker	n	<i>IFNG</i> +2200 TT ^{a,b}	n	<i>IFNG</i> +2200 CT/CC ^{a,b}	Adj P [†]	Bf adj P [*]
Hepcidin (ng/ml)	500	4.4 (3.8, 5.1)	84	3.2 (2.2, 4.6)	0.09	0.44
Hepcidin/ferritin	500	0.20 (0.18, 0.23)	84	0.18 (0.14, 0.25)	0.19	0.94
TSAT/hepcidin (%/ng/ml)	490	2.75 (2.38, 3.17)	81	3.33 (2.38, 4.67)	0.87	1
Ferritin (µg/L)	545	21.4 (19.7, 23.2)	91	16.9 (13.6, 21.1)	0.04	0.21
ZnPP (µmol/mol Hb)	550	112.4 (107.2, 117.8)	91	121.2 (107.0, 137.3)	0.06	0.32
sTfR (mg/L)	508	4.2 (4.0, 4.3)	86	4.2 (3.9, 4.6)	0.38	1
UIBC (µmol/L)	530	61.6 (60.1, 63.2)	87	67.9 (62.6, 73.8)	0.04	0.19
Serum iron (µmol/L)	532	8.6 (8.3, 8.9)	88	7.9 (7.1, 8.7)	0.19	0.95
TSAT (%)	528	12.0 (11.4, 12.5)	87	10.1 (8.8, 11.6)	0.04	0.19
Hb (g/dL)	546	10.0 (9.8, 10.1)	92	9.7 (9.4, 10.1)	0.006	0.03

^a Values are geometric means (95% confidence interval); ^b The wild-type alleles represent children with *IFNG*+2200TT genotype (n=598). The mutant alleles represent children with the *IFNG*+2200TC (n=93) and *IFNG*+2200CC (n=4) genotypes combined; [†] Significance values were derived by multivariable linear regression with each log-transformed iron marker as a dependent variable and adjusted for age, sex, village (a proxy for location and ethnic group), α_1 -antichymotrypsin level and the presence of malaria parasites on blood film. ^{*} P values adjusted for Bonferroni correction for the five tested SNPs. n, number of children; Hb, haemoglobin; ZnPP, zinc protoporphyrin; sTfR, soluble transferrin receptor; UIBC, unsaturated iron binding capacity; and TSAT, transferrin saturation.

Table 4. *IFNG* haplotypes and risk of iron deficiency, iron deficiency anaemia and anaemia at the end of the malaria season.

Hap ID	Haplotype ^a	Freq (No)	Iron Deficiency ^b		Iron Deficiency Anaemia ^c		Anaemia ^d	
			OR (95% CI) [†]	Adj P [†]	OR (95% CI) [†]	Adj P [†]	OR (95% CI) [†]	Adj P [†]
Hap1	CATTC	0.35 (536)	Reference		Reference		Reference	
Hap2	TATT T	0.19 (283)	0.82 (0.55, 1.21)	0.31	0.69 (0.44, 1.07)	0.10	1.08 (0.72, 1.60)	0.72
Hap3	TTT CC	0.16 (240)	0.70 (0.46, 1.06)	0.09	0.68 (0.43, 1.08)	0.10	0.83 (0.56, 1.24)	0.37
Hap4	CATT T	0.11 (171)	1.14 (0.73, 1.78)	0.73	0.91 (0.53, 1.56)	0.73	0.78 (0.50, 1.23)	0.28
Hap5	TAT CC	0.11 (166)	1.19 (0.77, 1.85)	0.58	0.91 (0.53, 1.55)	0.73	1.03 (0.65, 1.66)	0.89
Hap6	CA CTC	0.07 (100)	1.58 (0.93, 2.69)	0.09	1.71 (0.94, 3.10)	0.09	1.67 (0.93, 3.01)	0.09

^a The haplotype configuration is as follows: *IFNG*-1616, *IFNG*+874, *IFNG*+2200, *IFNG*+3234, *IFNG*+5612. Minor alleles are indicated by bold type; ^b ferritin <12µg/l (or ferritin<30µg/l in the presence of inflammation or <15 µg/L in children ≥5 years)³²; ^c iron deficiency and anaemia; ^d haemoglobin<11.0g/dL (or haemoglobin<11.5g/dL in children ≥5years); [†] odds ratios (OR) and P values were derived by multivariable logistic regression adjusted for age, sex, village, α_1 -antichymotrypsin level and malaria parasitaemia. Hap, haplotype; Freq, frequency of the haplotypes in the study population; no, number of haplotype alleles in the study population.

at the end of a malaria season in multivariable analyses adjusting for potential confounders. We then constructed haplotypes to increase the probability of capturing functional mutations which might reside within a given haplotype. Haplotype 6 (uniquely identified by the *IFNG*+2200C allele), was associated with reduced haemoglobin levels and TSAT and increased ZnPP levels in keeping with iron deficiency compared to

the wild-type haplotype. Haplotype 6 was similarly associated with trends towards increased risk of ID, IDA and anaemia at the end of the malaria season.

So how might the *IFNG*+2200C genotype and a haplotype uniquely defined by this genotype potentially lead to reduced haemoglobin levels and ID at the end of the malaria season?

Table 5. /FNG haplotypes and markers of iron status at the end of the malaria season.

Hap	Hepcidin (ng/ml)	AdjP ¹	Ferritin (µg/L)	Adj P ²	ZnPP (µmol/mol Hb)	Adj P ²	TSAT (%)	Adj P ²	sTfR (mg/L)	Adj P ²	Hb (g/dl)	Adj P ²
CATC	4.3 (3.7, 5.0)	Ref	19.4 (17.8, 21.1)	Ref	115.3 (109.6, 121.3)	Ref	11.5 (11.0, 12.1)	Ref	4.2 (4.0, 4.3)	Ref	10.0 (9.8, 10.1)	Ref
TATT	4.5 (3.5, 5.6)	0.69	22.3 (19.7, 25.3)	0.06	113.0 (105.0, 121.6)	0.41	11.7 (11.0, 12.6)	0.93	4.2 (4.0, 4.4)	0.76	9.9 (9.7, 10.1)	0.22
TTCC	4.3 (3.3, 5.5)	0.95	24.4 (21.3, 27.9)	0.05	115.1 (107.3, 123.5)	0.54	11.3 (10.4, 12.4)	0.58	4.1 (3.9, 4.4)	0.50	10.0 (9.7, 10.2)	0.85
CATT	5.2 (4.0, 6.7)	0.28	20.9 (17.8, 20.5)	0.54	103.8 (95.9, 112.4)	0.26	12.9 (11.9, 14.0)	0.09	4.0 (3.8, 4.3)	0.30	10.2 (9.9, 10.4)	0.31
TATC	3.5 (2.6, 4.7)	0.16	18.8 (16.0, 22.1)	0.64	109.3 (99.5, 120.1)	0.87	11.5 (10.5, 12.6)	0.92	4.2 (4.0, 4.5)	0.80	10.0 (9.8, 10.3)	0.74
CACTC	3.2 (2.3, 4.6)	0.11	16.6 (13.4, 20.5)	0.08	123.5 (109.1, 139.8)	0.02	9.8 (8.5, 11.3)	0.02	4.2 (3.9, 4.6)	0.28	9.7 (9.3, 10.0)	0.002

Values are geometric means (95% confidence interval). ¹ Significance (P) values were derived by multivariable linear regression with each log-transformed iron marker as a dependent variable and adjusted for age, sex, village (a proxy for location and ethnic group), α 1-antichymotrypsin level and the presence of malaria parasites on blood film. Hap, haplotype; Hb, haemoglobin; ZnPP, zinc protoporphyrin; sTfR, soluble transferrin receptor; and TSAT, transferrin saturation.

A possible explanation may be through increasing *IFNG* gene expression and IFN- γ levels. The *IFNG*+2200C allele was associated with increased IFN- γ levels in Kawasaki disease patients²³, although another study in patients with ankylosing spondylitis found no difference in IFN- γ levels by *IFNG*+2200 genotype³⁵. Elevated IFN- γ levels promote dyserythropoiesis, anaemia and iron dysregulation. IFN- γ inhibits proliferation of erythroid progenitor cells by disrupting lineage differentiation, blocking renal production of erythropoietin, inhibiting renal iron reabsorption, and reducing red blood cell half-life^{14–16,36}. As a type 1 immune response, IFN- γ also induces defensive transcriptional programs within enterocytes resulting in reduced dietary iron absorption³⁷. Additionally, IFN- γ promotes iron sequestration in macrophages either directly or through its influence on hepcidin, ferroportin, and DMT1^{17–20}. These responses reduce circulating transferrin-bound iron, which is required by *Plasmodium* parasites for metabolism and proliferation³⁸. In keeping with this, we observed decreased ferritin levels and TSAT and increased ZnPP levels in children carrying the *IFNG*+2200C haplotype. Lower haemoglobin levels may also translate into reduced amino acid availability for *Plasmodium* parasites³⁹ and hence protection against blood-stage parasitaemia. Indeed, we observed that the *IFNG*+2200C SNP was associated with protection against malaria parasitaemia at the end of the malaria season (adj. OR 0.40; Bonferroni adj. P=0.03).

The influence of the *IFNG*+2200C allele on haemoglobin and iron status was only observed at the end of the malaria season. We hypothesized that the effects of this SNP may be most marked when expression of *IFNG* is upregulated, such as during malaria infections^{13,24}. This also highlights the influence of gene-environment interactions in promoting disease, in this case ID, IDA and anaemia. It is unlikely that the decreased haemoglobin levels observed in individuals carrying the *IFNG*+2200C allele was due to increased malaria since these children had reduced prevalence of malaria parasitaemia at the end of the malaria season. It is possible that higher IFN- γ levels, putatively produced by *IFNG*+2200C carriers, may induce a protective proinflammatory response against malaria^{13,40}, but at the expense of iron homeostasis. The *IFNG*+874TT (rs2430561) genotype, located at the first intron coinciding with the NFkB binding region, has also been associated with higher production of IFN- γ ^{22,35,41}. However, studies have found no association between *IFNG*+874TT and malaria²⁵ or aplastic anaemia⁴², and in our study we observed a trend towards a decreased risk of ID in these individuals. Further investigations are required on a cellular level to explore putative functional effects of *IFNG* genotypes on IFN- γ levels and iron status.

To our knowledge, this is the first study examining the role of *IFNG* gene polymorphisms in relation to iron status. We found that the *IFNG*+2200C (rs1861493) allele, and a haplotype defined by this allele, were associated with reduced

haemoglobin levels and a trend towards ID at the end of the malaria season, a finding that may be due to increased IFN- γ levels²³. However, our study had a number of important limitations and our findings should be viewed with considerable caution. The study was conducted in a single site and had relatively small numbers (n = 756). Additionally, many of our findings were of marginal significance with wide confidence intervals and lost statistical significance after correction for multiple testing with Bonferroni adjustment. It is also unclear if our findings have clinical relevance at an individual level. The *IFNG*+2200C SNP may also be in linkage disequilibrium (LD) with another genetic variant within the haplotype that might influence IFN- γ levels and / or measures of iron status in Gambian populations. Finally, we did not measure IFN- γ levels to determine if they differed between genotypes at the end of the malaria season. Thus, our findings need to be examined in larger population-based studies, in other malaria-exposed populations, and functional assays are needed to identify whether genetic variation in the *IFNG* gene influences iron status. However, our study supports the hypothesis that preventing and treating malaria infection may improve haemoglobin levels and iron status in African children⁸.

Data availability

Underlying data

Harvard Dataverse: Replication Data for: Interferon-gamma polymorphisms and risk of iron deficiency and anaemia in Gambian children, <https://doi.org/10.7910/DVN/2NKJID>⁴³. This project contains the following underlying data:

- *IFNG_final_data_v2* (dataset containing demographic information and results of laboratory assays for participants included in the study).
- *IFNG_analysis_KM* (contains the codes used for data analysis).
- *KMokaya_IFNG_Codebook* (contains variable description and labels).
- Data are available under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/) (CC-BY 4.0).

Extended Data

Figshare: *IFNG* polymorphisms in Gambian children and risk of iron deficiency and anaemia, <https://doi.org/10.6084/m9.figshare.11807277.v6>²⁹.

This project contains the following extended data:

Extended datafile 1. Assayed *IFNG* single nucleotide polymorphisms

Extended datafile 2. Agena Biosciences (formerly SEQUENOM) MassARRAY® primer-extension definitions data for the five *IFNG* polymorphisms

Extended datafile 3. Markers of iron status at the end of the malaria season in children with sickle cell trait and glucose-6-phosphate dehydrogenase deficiency

Extended datafile 4. *IFNG* single nucleotide polymorphisms and risk of malaria parasitemia at the start and end of the malaria season

Extended datafile 5. *IFNG* genotypes and risk of iron deficiency, iron deficiency anaemia and anaemia at the start of the malaria season

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Acknowledgements

We thank the children that took part in this study and their parents. We would also like to thank the Keneba fieldworkers for their assistance in the field and laboratory. This manuscript was submitted for publication with the permission of the Director of the Kenya Medical Research Institute (KEMRI).

References

- World Health Organization: **World malaria report 2019**. 2019. [Reference Source](#)
- Snow RW, Sartorius B, Kyalo D, *et al.*: **The prevalence of *Plasmodium falciparum* in sub-Saharan Africa since 1900**. *Nature*. 2017; **550**(7677): 515–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- World Health Organization: **The global prevalence of anaemia in 2011**. 2015. [Reference Source](#)
- Kassebaum NJ, Jasrasaria R, Naghavi M, *et al.*: **A systematic analysis of global anemia burden from 1990 to 2010**. *Blood*. 2014; **123**(5): 615–24. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Markova V, Holm C, Pinborg AB, *et al.*: **Impairment of the Developing Human Brain in Iron Deficiency: Correlations to Findings in Experimental Animals and Prospects for Early Intervention Therapy**. *Pharmaceuticals (Basel)*. 2019; **12**(3): 120. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Georgieff MK: **Long-term brain and behavioral consequences of early iron deficiency**. *Nutr Rev*. 2011; **69** Suppl 1: S43–S8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators: **Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016**. *Lancet*. 2017; **390**(10100): 1211–59. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Muriuki JM, Atkinson SH: **How Eliminating Malaria May Also Prevent Iron Deficiency in African Children**. *Pharmaceuticals (Basel)*. 2018; **11**(4): 96. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Spottiswoode N, Duffy PE, Drakesmith H: **Iron, anemia and hepcidin in malaria**. *Front Pharmacol*. 2014; **5**: 125. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Atkinson SH, Armitage AE, Khandwala S, *et al.*: **Combinatorial effects of malaria season, iron deficiency, and inflammation determine plasma hepcidin concentration in African children**. *Blood*. 2014; **123**(21): 3221–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Atkinson SH, Rockett KA, Morgan G, *et al.*: **Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children**. *Blood*. 2008; **112**(10): 4276–83. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Frosch AE, Ondigo BN, Ayodo GA, *et al.*: **Decline in childhood iron deficiency after interruption of malaria transmission in highland Kenya**. *Am J Clin Nutr*. 2014; **100**(3): 968–73. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- McCall MB, Sauerwein RW: **Interferon- γ -central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria**. *J Leukoc Biol*. 2010; **88**(6): 1131–43. [PubMed Abstract](#) | [Publisher Full Text](#)
- Zombos NC, Djeu JY, Young NS: **Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes *in vitro***. *J Immunol*. 1984; **133**(2): 769–74. [PubMed Abstract](#)
- Libregts SF, Gutiérrez L, de Bruin AM, *et al.*: **Chronic IFN- γ production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis**. *Blood*. 2011; **118**(9): 2578–88. [PubMed Abstract](#) | [Publisher Full Text](#)
- Lin FC, Karwan M, Saleh B, *et al.*: **IFN- γ causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation**. *Blood*. 2014; **124**(25): 3699–708. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Frazier MD, Mamo LB, Ghio AJ, *et al.*: **Hepcidin expression in human airway epithelial cells is regulated by interferon- γ** . *Respir Res*. 2011; **12**(1): 100. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Nairz M, Fritsche G, Brunner P, *et al.*: **Interferon-gamma limits the availability of iron for intramacrophage *Salmonella typhimurium***. *Eur J Immunol*. 2008; **38**(7): 1923–36. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ludwiczek S, Aigner E, Theurl I, *et al.*: **Cytokine-mediated regulation of iron transport in human monocytic cells**. *Blood*. 2003; **101**(10): 4148–54. [PubMed Abstract](#) | [Publisher Full Text](#)
- Byrd TF, Horwitz MA: **Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon gamma**. *J Clin Invest*. 1993; **91**(3): 969–76. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Raballah E, Kempaiah P, Karim Z, *et al.*: **CD4 T-cell expression of IFN- γ and IL-17 in pediatric malarial anemia**. *PLoS One*. 2017; **12**(4): e0175864. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Pravica V, Perrey C, Stevens A, *et al.*: **A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production**. *Hum Immunol*. 2000; **61**(9): 863–6. [PubMed Abstract](#) | [Publisher Full Text](#)
- Huang YH, Hsu YW, Lu HF, *et al.*: **Interferon-gamma Genetic Polymorphism and Expression in Kawasaki Disease**. *Medicine (Baltimore)*. 2016; **95**(17): e3501. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cabantous S, Poudiougou B, Traore A, *et al.*: **Evidence that interferon-gamma plays a protective role during cerebral malaria**. *J Infect Dis*. 2005; **192**(5): 854–60. [PubMed Abstract](#) | [Publisher Full Text](#)
- Koch O, Rockett K, Jallow M, *et al.*: **Investigation of malaria susceptibility determinants in the IFNG/IL26/IL22 genomic region**. *Genes Immun*. 2005; **6**(4): 312–8. [PubMed Abstract](#) | [Publisher Full Text](#)
- Atkinson SH, Rockett K, Sirugo G, *et al.*: **Seasonal childhood anaemia in West Africa is associated with the haptoglobin 2-2 genotype**. *PLoS Med*. 2006; **3**(5): e172. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yamanishi H, Iyama S, Yamaguchi Y, *et al.*: **Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity**. *Clin Chem*. 2003; **49**(1): 175–8. [PubMed Abstract](#) | [Publisher Full Text](#)
- Donker AE, Galesloot TE, Laarakkers CM, *et al.*: **Standardized serum hepcidin values in Dutch children: Set point relative to body iron changes during childhood**. *Pediatr Blood Cancer*. 2020; **67**(3): e28038. [PubMed Abstract](#) | [Publisher Full Text](#)
- Abuga KM, Robert KA, Muriuki J, *et al.*: **IFNG polymorphisms in Gambian children and risk of iron deficiency and anaemia**. *figshare*. Figure. 2020. <http://www.doi.org/10.6084/m9.figshare.11807277.v6>
- Hanchard N, Diakite M, Koch O, *et al.*: **Implications of inter-population linkage disequilibrium patterns on the approach to a disease association study in the human MHC class III**. *Immunogenetics*. 2006; **58**(5–6): 465–70. [PubMed Abstract](#) | [Publisher Full Text](#)

31. Stephens M, Scheet P: **Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation.** *Am J Hum Genet.* 2005; **76**(3): 449–62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. World Health Organization: **Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations.** 2011.
[Reference Source](#)
33. World Health Organization: **Iron deficiency anemia. assessment, prevention, and control: A guide for programme managers.** 2001.
[Reference Source](#)
34. Shaffer JP: **Multiple hypothesis testing.** *Ann Rev Psychol.* 1995; **46**(1): 561–84.
[Publisher Full Text](#)
35. Xu H, Li B: **Effect of Interferon- γ Polymorphisms on Ankylosing Spondylitis: A Case-Control Study.** *Med Sci Monit.* 2017; **23**(1): 4126–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Vannucchi AM, Grossi A, Rafanelli D, *et al.*: **Inhibition of erythropoietin production *in vitro* by human interferon gamma.** *Br J Haematol.* 1994; **87**(1): 18–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Colgan SP, Parkos CA, Matthews JB, *et al.*: **Interferon-gamma induces a cell surface phenotype switch on T84 intestinal epithelial cells.** *Am J Physiol.* 1994; **267**(2 Pt 1): C402–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Pollack S, Fleming J: ***Plasmodium falciparum* takes up iron from transferrin.** *Br J Haematol.* 1984; **58**(2): 289–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Liu J, Istvan ES, Gluzman IY, *et al.*: ***Plasmodium falciparum* ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems.** *Proc Natl Acad Sci U S A.* 2006; **103**(23): 8840–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. D'Ombrain MC, Robinson LJ, Stanisic DI, *et al.*: **Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children.** *Clin Infect Dis.* 2008; **47**(11): 1380–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Sallakci N, Coskun M, Berber Z, *et al.*: **Interferon-gamma gene+874T-A polymorphism is associated with tuberculosis and gamma interferon response.** *Tuberculosis (Edinb).* 2007; **87**(3): 225–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Razi B, Alizadeh S, Imani D, *et al.*: **Interferon-Gamma +874 (T/A) Polymorphism and Susceptibility to Aplastic Anemia: A Systematic Review and Meta-Analysis.** *Evid Based Med Pract.* 2017; **3**(112): 2.
[Publisher Full Text](#)
43. Abuga KM, Rockett KA, Muriuki JM, *et al.*: **Replication Data for: Interferon-gamma polymorphisms and risk of iron deficiency and anaemia in Gambian children.** Harvard Dataverse, V1, 2020.
<http://www.doi.org/10.7910/DVN/2NKJID>

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 05 May 2020

<https://doi.org/10.21956/wellcomeopenres.17270.r38445>

© 2020 Silvestri L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Laura Silvestri

Regulation of Iron Metabolism Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy

In this paper Abuga et al investigate the role of IFNG SNPs in influencing iron deficiency (ID) and iron deficiency anemia (IDA) in Gambian children over a malaria season. They identify a SNP, IFNG+2200C, located in intron 3, associated with a reduced risk of malaria parasitemia, reduced Hb, and a trend towards ID and IDA. The authors conclude that although more studies are needed to assess the role of IFNG SNPs in ID and IDA, this represents the first study that investigates the association of IFNG genetic variants with iron status.

The study is well conducted and of interest. I have only minor comments:

1. Serum hepcidin levels are influenced by circadian rhythm and serum/iron stores. Please indicate at what time of the day blood was drawn. To “normalize” serum hepcidin to body iron concentration, the hepcidin/ferritin or hepcidin/TSAT ratio should be shown in Table 1 and Table 3 (as in Donker et al., *Pediatric Blood and Cancer* 2019¹).
2. In the M&M section, the authors claim that some children are carriers of the HbAS, and G6PD deficiency. Is it possible to present the hematological and iron data (in Table 1 and Table 3) related to these children?

References

1. Donker AE, Galesloot TE, Laarakkers CM, Klaver SM, et al.: Standardized serum hepcidin values in Dutch children: Set point relative to body iron changes during childhood. *Pediatr Blood Cancer*. **67** (3): e28038 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Laura Silvestri has long-term expertise in the characterization of molecular mechanisms responsible for the pathogenesis of iron/hepcidin-related disorders as Hereditary Hemochromatosis, beta-thalassemia, and iron refractory iron deficiency anemia (IRIDA).

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 27 May 2020

Sarah Atkinson, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Thank you for your helpful comments.

- 1. a) Serum hepcidin levels are influenced by circadian rhythm and serum/iron stores. Please indicate at what time of the day blood was drawn.**

Response: Thank you, Blood was drawn from the participants in the morning hours (between 6 and 11AM). We have updated the study design section to indicate the time of sample collection.

Methods, under Study design: "All children had a clinical examination and a blood sample collected in the morning between 6 and 11 am for full blood count, malaria film, and biomarkers of iron status and inflammation at the start and end of the malaria season."

- b) To "normalize" serum hepcidin to body iron concentration, the hepcidin/ferritin or hepcidin/TSAT ratio should be shown in Table 1 and Table 3 (as in Donker et al., Pediatric Blood and Cancer 2019).**

Response: Thank you for the suggestion. We have added hepcidin/ferritin and transferrin saturation (TSAT)/hepcidin ratios to tables 1 and 3. We have also made the following changes:

Methods section under laboratory methods: Hepcidin/ferritin and TSAT/hepcidin ratios were also calculated.¹

Results section under Characteristics of participants: We found that hepcidin and hepcidin/ferritin ratio decreased while the TSAT/hepcidin ratio increased across the malaria season in keeping with

the need for increased erythropoiesis and increased rates of iron absorption at the end of the malaria season.

2. In the M&M section, the authors claim that some children are carriers of the HbAS, and G6PD deficiency. Is it possible to present the haematological and iron data (in Table 1 and Table 3) related to these children?

Response: Thank you for this suggestion. We have now added haemoglobin and iron biomarker data for children with HbAS and G6PD deficiency as a Supplementary file (Extended datafile 3) that can be accessed on Figshare (<https://doi.org/10.6084/m9.figshare.11807277.v6>). We have also made the following changes to the Results section:

Results under Characteristics of participants: "A total of 99/751 (13.2%) children carried sickle cell trait (HbAS) and 136/683 (19.9%) children G6PD deficiency and the effects of these polymorphisms on iron status and anaemia are shown in Extended datafile 3.² At the start of the malaria season we found little difference in iron status in children with HbAS and G6PD deficiency compared to those with wild-type. At the end of the malaria season, children carrying HbAS had lower zinc protoporphyrin levels (97.0 [95% CI 87.0, 108.2]) compared to those with HbAA (115.9 [95% CI 110.6, 121.3]; adj. P = 0.05) and children with G6PD deficiency had lower haemoglobin levels (9.7 g/dl [95% CI 9.4, 10.0]) than those with G6PD wild-type genotype (10.0 g/dl [95% CI 9.9, 10.2]; adj. P = 0.01)."

References

1. Donker AE, Galesloot TE, Laarakkers CM, Klaver SM, Bakkeren DL, Swinkels DW. Standardized serum hepcidin values in Dutch children: Set point relative to body iron changes during childhood. *Pediatr Blood Cancer* 2020; **67**(3): e28038.
2. Abuga KM, Robert KA, Muriuki JM, et al. IFNG polymorphisms in Gambian children and risk of iron deficiency and anaemia. 2020. <https://doi.org/10.6084/m9.figshare.11807277>.

Competing Interests: No competing interests were disclosed.

Reviewer Report 23 April 2020

<https://doi.org/10.21956/wellcomeopenres.17270.r38239>

© 2020 Ong'echa J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



John Michael Ong'echa

Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya

Abstract:

It would be good if the authors provided the age range of children enrolled in the study (2 – 6 years). This could be added in the Methods section at the end of the sentence '...780 Gambian children.'

The last sentence at the end of the Results section mentions a number of covariates that were adjusted for in the models. One such covariate is 'malaria parasitaemia'.

Was malaria parasitaemia adjusted for only at the beginning and at the end of the malaria season or did it capture all the malaria cases during the study period? Does 'malaria parasitaemia' mean malaria episodes during the study period? If it only captures the two time points, what would the effect of 'additional episodes' during the study period have on the results? In malaria endemic areas, repeated infections are more likely to result in anaemia than just the patent infection.

The authors need to clarify on this and if there were no malaria cases in-between the two time-points they need to indicate so.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 27 May 2020

Sarah Atkinson, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

We thank the reviewer for his helpful comments, which we have addressed point-by-point below:

Reviewer #1

1. **Abstract: It would be good if the authors provided the age range of children enrolled in the study (2 – 6 years). This could be added in the Methods section at the end of the sentence '...780 Gambian children.'**

Response: Thank you for the suggestion. We have added the age range (2-6 years) in the methods section of the abstract.

Abstract, Methods: "We used previously available data from Gambian family trios to determine informative SNPs and then used the Agena Bioscience MassArray platform to type five SNPs from

the IFNG gene in a cohort of 780 Gambian children aged 2-6 years”.

2. The last sentence at the end of the Results section mentions a number of covariates that were adjusted for in the models. One such covariate is ‘malaria parasitaemia’.

a) Was malaria parasitaemia adjusted for only at the beginning and at the end of the malaria season or did it capture all the malaria cases during the study period?

Response: In the current analysis, we adjusted for malaria parasitaemia detected on blood film at the beginning and at the end of the malaria season, at the same timepoints when iron biomarkers were measured since malaria parasitaemia influences markers of iron status. We did not monitor for malaria cases during the malaria season.

Methods, under Statistical analyses: “Multivariable regression models were adjusted for age (grouped by year), sex, village (which also acted as a proxy for ethnic group), malaria parasitaemia and ACT at the start and end of the malaria season.”

b) Does ‘malaria parasitaemia’ mean malaria episodes during the study period?

Response: Malaria parasitaemia referred to the identification of Plasmodium parasites on the blood film taken from the study participants at either of the two cross-sectional timepoints, i.e. at the beginning and / or end of the malaria season. It does not refer to malaria episodes during the study period.

c) If it only captures the two time points, what would the effect of ‘additional episodes’ during the study period have on the results? In malaria endemic areas, repeated infections are more likely to result in anaemia than just the patent infection. The authors need to clarify on this and if there were no malaria cases in-between the two time-points they need to indicate so.

Response: We agree that repeated malaria episodes would increase the risk of anaemia. Based on published data we estimated that the majority of the children would be likely to have had one or more episodes of malaria over the malaria season during the study period.¹ Studies indicate that malaria increases IFN-g levels² and that IFN-g regulates erythropoiesis and iron-regulatory proteins including hepcidin.³⁻⁶ We therefore hypothesized that IFNG SNPs, which might alter IFNG expression, would influence iron status at the end of the malaria season. Thus, we would expect that the effect of ‘additional episodes’ of malaria would be to increase malaria-induced IFN-g levels and IFN-g -induced iron deficiency and anaemia. To clarify we have updated the Methods section as follows:

Methods, under Laboratory methods: “Giemsa-stained thick and thin blood films were examined for Plasmodium falciparum and other Plasmodium species at the start and end of the malaria season.”

Competing Interests: No competing interests were disclosed.

Author Response 27 May 2020

Sarah Atkinson, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

We thank the reviewer for his helpful comments, which we have addressed point-by-point below:

- 1. Abstract: It would be good if the authors provided the age range of children enrolled in the study (2 – 6 years). This could be added in the Methods section at the end of the sentence ‘...780 Gambian children.’**

Response: Thank you for the suggestion. We have added the age range (2-6 years) in the methods section of the abstract.

Abstract, Methods: “We used previously available data from Gambian family trios to determine informative SNPs and then used the Agena Bioscience MassArray platform to type five SNPs from the IFNG gene in a cohort of 780 Gambian children aged 2-6 years”.

- 2. The last sentence at the end of the Results section mentions a number of covariates that were adjusted for in the models. One such covariate is ‘malaria parasitaemia’.**

- a) Was malaria parasitaemia adjusted for only at the beginning and at the end of the malaria season or did it capture all the malaria cases during the study period?**

Response: In the current analysis, we adjusted for malaria parasitaemia detected on blood film at the beginning and at the end of the malaria season, at the same timepoints when iron biomarkers were measured since malaria parasitaemia influences markers of iron status. We did not monitor for malaria cases during the malaria season.

Methods, under Statistical analyses: “Multivariable regression models were adjusted for age (grouped by year), sex, village (which also acted as a proxy for ethnic group), malaria parasitaemia and ACT at the start and end of the malaria season.”

- b) Does ‘malaria parasitaemia’ mean malaria episodes during the study period?**

Response: Malaria parasitaemia referred to the identification of Plasmodium parasites on the blood film taken from the study participants at either of the two cross-sectional timepoints, i.e. at the beginning and / or end of the malaria season. It does not refer to malaria episodes during the study period.

- c) If it only captures the two time points, what would the effect of ‘additional episodes’ during the study period have on the results? In malaria endemic areas, repeated infections are more likely to result in anaemia than just the patent infection. The authors need to clarify on this and if there were no malaria cases in-between the two time-points they need to indicate so.**

Response: We agree that repeated malaria episodes would increase the risk of anaemia. Based on published data we estimated that the majority of the children would be likely to have had one or more episodes of malaria over the malaria season during the study period.¹ Studies indicate that malaria increases IFN-g levels² and that IFN-g regulates erythropoiesis and iron-regulatory proteins including hepcidin.³⁻⁶ We therefore hypothesized that IFNG SNPs, which might alter IFNG expression, would influence iron status at the end of the malaria season. Thus, we would expect that the effect of ‘additional episodes’ of malaria would be to increase malaria-induced IFN-g levels and IFN-g -induced iron deficiency and anaemia. To clarify we have updated the Methods

section as follows:

Methods, under Laboratory methods: "Giemsa-stained thick and thin blood films were examined for Plasmodium falciparum and other Plasmodium species at the start and end of the malaria season."

References

1. Ceesay SJ, Casals-Pascual C, Erskine J, et al. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. *Lancet (London, England)* 2008; **372**(9649): 1545-54.
2. McCall MB, Sauerwein RW. Interferon-gamma--central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria. *Journal of leukocyte biology* 2010; **88**(6): 1131-43.
3. Frazier MD, Mamo LB, Ghio AJ, Turi JL. Hepcidin expression in human airway epithelial cells is regulated by interferon- γ . *Respiratory research* 2011; **12**(1): 100.
4. Nairz M, Fritsche G, Brunner P, Talasz H, Hantke K, Weiss G. Interferon-gamma limits the availability of iron for intramacrophage *Salmonella typhimurium*. *European journal of immunology* 2008; **38**(7): 1923-36.
5. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. *Blood* 2003; **101**(10): 4148-54.
6. Byrd TF, Horwitz MA. Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes. Coordinate upregulation by iron transferrin and downregulation by interferon gamma. *The Journal of clinical investigation* 1993; **91**(3): 969-76.

Competing Interests: No competing interests were disclosed.